The Quantellect read.As of Nov 19, 2026, 5 active firms cover Altimmune Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $10.00 to $20.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $14.20 sits 929% above the current $1.38. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees revenue growth near -89% this year and -100% next, consensus EPS building from about $-0.17 next quarter toward $-0.71 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$14.20
+929.0% upside
Average target across 5 active firms as of Nov 19, 2026 vs $1.38 current
Highest Target$20.00
Average Target$14.20
Lowest Target$10.00
Detailed analyst forecasts for ALT
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate ALT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ALT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.19 – $-0.13 · 5 analysts · -7% YoY
Next period, 5 analysts expect Altimmune Inc to earn $-0.17 a share (range $-0.19 – $-0.13), versus $-0.18 a year earlier. Full-year consensus is $-0.63, growing to $-0.71 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts · -69% YoY
Revenue is expected to reach $0 (range $0 – $0), -69.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Altimmune Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ALT.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$18.00+1204.3% to target
Overall win rate
49%
+ Follow
#2
Jonathan Wolleben
JMP Securities · Rank #54
Buy
$11.00+697.1% to target
Overall win rate
43%
+ Follow
#3
Roger Song
Jefferies · Rank #122
Buy
$28.00+1929.0% to target
Overall win rate
43%
+ Follow
#4
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$20.00+1349.3% to target
Overall win rate
36%
+ Follow
#5
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$25.00+1711.6% to target
Overall win rate
30%
+ Follow
ALT stock forecast FAQ
What is ALT's average 12-month price target?+
The 5 active firms with a live target average $14.20 for Altimmune Inc over the next 12 months, ranging from a $20.00 high to a $10.00 low, as of Nov 19, 2026.
Is ALT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ALT?+
The Street-high target is $20.00 (HC Wainwright & Co.), and the Street-low is $10.00 (Leerink Partners). The average of all 5 active-firm targets is $14.20.
How many active Wall Street firms cover ALT?+
5 active firms have a recognized rating on Altimmune Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ALT?+
Among analysts who currently cover ALT, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $18.00 target.
What is Altimmune Inc's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.19 – $-0.13) across 5 analysts. Full-year EPS is projected at $-0.63, rising to $-0.71 the following year.
How much revenue is Altimmune Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ALT lately?+
As of Nov 19, 2026, 5 of 5 active firms rate ALT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ALT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.